The results of two phase 3 trials investigating Survodutide, a weight loss drug from Boehringer Ingelheim, suggest that the ...

Across 76 weeks in obesity/overweight without type 2 diabetes, survodutide achieved up to 16.6% mean weight loss versus 3.2% ...

Consuming a high-fat diet can lead to a variety of health problems—not only weight gain but also an increased risk of diabetes and other chronic diseases. At the cellular level, hundreds of changes ...

Northwestern Medicine scientists led by Joseph Bass, MD, Ph.D., the Charles F. Kettering Professor of Endocrinology and Metabolism and director of the Center for Diabetes and Metabolism, have ...

Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing ...

Your weight may look normal on the scale, but dangerous fat hidden around your organs could still be increasing your risk of ...

Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to ...

AI company unlocking causal human biology, today presented new preclinical data from its metabolic dysfunction-associated steatohepatitis (MASH) therapeutic development program during a podium ...

Phase 3 data show survodutide normalized liver fat in 61% of patients with MASLD while reducing weight, visceral fat, and metabolic risk factors. At the American Diabetes Association 2026 Scientific ...